The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu), a human FcRn-blocking ...

University of Miami Miller School of Medicine researchers have identified molecular evidence linking human papillomavirus ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Tetanus-diphtheriaa-acellular pertussis–inactivated polio virus vaccination during pregnancy is safe and boosts ...

House: Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for IMAAVY (nipocalimab-aahu) ...

Amsterdam, the Netherlands Tuesday, April 29, 2025, 10:00 Hrs [IST] ...

A mother gives her baby immunity even before birth. Vaccines during pregnancy protect both, boosting the baby's defense ...